RSV is the main cause of severe respiratory infections in infants and young children in Germany - data from the prospective, multicenter PAPI study 2021-2023
- PMID: 39971837
- PMCID: PMC12460574
- DOI: 10.1007/s15010-025-02484-1
RSV is the main cause of severe respiratory infections in infants and young children in Germany - data from the prospective, multicenter PAPI study 2021-2023
Abstract
Background: Respiratory syncytial virus (RSV) is one of the main causes of morbidity in infants and young children worldwide. Current data on RSV-associated disease burden in Germany before the introduction of new immunization strategies is lacking.
Methods: The PAPI study is a multicenter, prospective surveillance study of lower respiratory tract infections (LRTI) in children aged ≤ 24 months in Germany.
Results: Data from 1607 children with LRTI hospitalized in twelve German hospitals between September 2021 and May 2023 were analyzed. Among these children, RSV was the most frequently detected pathogen (57.1%), followed by rhino/entero-, metapneumo- and parainfluenza virus. Children with RSV were significantly younger than those with LRTI of other causes (mean of 5.6 ± SD 6.1 vs. mean of 10.1 ± SD 7.3 months, p < 0.001) and more frequently affected in their first six months of life. RSV positive children were significantly more likely to develop hypoxemia (61.9% vs. 44.3%, p < 0.001) and need for intravenous or enteral fluid supplementation (48.1% vs. 43.1%, p = 0.009; 13.2% vs. 5.9%, p < 0.001) than those without RSV.
Conclusion: RSV is the dominant pathogen for LRTI-associated hospitalizations in children ≤ 24 months in Germany and associated with a particularly high need for treatment. The ongoing implemented use of RSV immunization according to current recommendations could lead to significant reduction in early childhood morbidity in Germany.
Keywords: Disease burden; Hospitalization; Morbidity; RSV; Seasonality.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethical approval: The study was approved by the ethics committees of the participating centers (vote Medizinische Hochschule 9442_BO_K_2020 MHH). The legal guardians of each participating child were comprehensively informed about the study and gave their written consent. A strobe checklist added to the manuscript. Consent for publication: The manuscript does not contain any identifiable information about individual patients. Competing interests: The PAPI study is supported by funding from Sanofi and AstraZeneca. MW has received honoraria for lectures and consultancy work from AstraZeneca, Novartis, Sanofi, Pfizer and GSK. CH has received research funding from Novartis and Pari, in each case unrelated to the current project.
Figures
References
-
- Bryce J, Boschi-Pinto C, Shibuya K, Black RE, Group WHOCHER. WHO estimates of the causes of death in children. Lancet. 2005;365(9465):1147–52. - PubMed
-
- Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, Madhi SA, Omer SB, Simoes EAF, Campbell H, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–64. - PMC - PubMed
-
- Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, Poehling KA, Szilagyi PG, Griffin MR, Williams JV, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341–348. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical